Treatment & Guidelines
Treatment & Guidelines
The new 2021 ESC/EACTS VHD guidelines recommend that all* symptomatic patients with severe aortic stenosis (sAS) are referred to the Heart Team for a treatment evaluation. The Heart Team will assess multiple patient factors, including their age, their values and preferences, when making the final decision between TAVI and SAVR.1
* With treatment indication. 1
In this recorded webinar hear from leading cardiologist Dr. Shrilla Banerjee on:
In the fourth instalment of the TAVI Talk podcast series Interventional Cardiologists Dr. Sagar Doshi from The Queen Elizabeth Hospital, Birmingham and Dr. Charis Costopoulos from Royal Papworth Hospital discuss optimization of the pre, peri and post TAVI procedure.
Supported by proven results from PARTNER 3,1 low-risk patients with sAS now have the opportunity for TAVI. As these patients are usually younger and healthier than those in higher risk categories,1-6 further considerations for this group include valve durability and valve-in-valve (ViV) procedures that support their longer-term management.
In the third instalment of the TAVI Talk podcast series, Interventional Cardiologist Dr. Karim Ratib from Royal Stoke University Hospital and Dr. Andrew Epstein, Cardiologist from Wye Valley NHS Trust discuss their Aortic Stenosis Management Service for best patient outcome.
The characterisation of aortic stenosis (AS) severity remains an ongoing challenge in clinical practice. Patients with discordant echocardiographic indices are commonly described in reports as having less than sAS despite meeting the criteria for sAS. Understanding the limitations of echocardiographic and adopting a step-by-step integrative approach to confirm AS severity can help meet the challenge.1-3
Patients often reduce physical activity to avoid symptoms, making it challenging to correctly identify when symptoms do develop.1-4The added burden of COVID-19 risks exacerbating this through the risk of reduced hospital appointments and limited physical activity during lockdowns.5,6
In this episode interventional cardiologists and TAVI implanters, Professor Rajesh Kharbanda, Dr Sam Dawkins, Dr Clare Appleby and Dr Joe Mills discuss:
Treatment delays in patients with severe aortic stenosis (sAS) continue to impact outcomes. With COVID-19 putting a strain on healthcare resources — and delays in aortic stenosis (AS) treatment carrying a mortality risk that increases the longer the delay — early identification of sAS patients and timely referrals can help minimise these risks.1-3